EU/3/07/525: Orphan designation for the treatment of neuroblastoma

Iodine (131I) iobenguane

Table of contents


On 31 January 2008, orphan designation EU/3/07/525 was granted by the European Commission to Molecular Insight Limited, United Kingdom, for iodine (131I) iobenguane for the treatment of neuroblastoma.


Key facts

Active substance
Iodine (131I) iobenguane
Intended use
Treatment of neuroblastoma
Orphan designation status
EU designation number
Date of designation

Excelsior Life Sciences Ireland Limited
25/28 North Wall Quay 
North Wall 
Dublin 1 
Co. Dublin 
D01 H104 
Tel. +353 1649 2000

Update history

March 2023The sponsor's address was updated.
June 2019The sponsorship was transferred to Excelsior Life Sciences Ireland Limited, Ireland.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating